First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC
The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.
Related Articles
“Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender Medical group sues over removing “information used every day by health professions” – The Cancer Letter
The web page for the FDA Office of Minority Health and Health Equity is no more. To access this subscriber-only content please log in or…
How blood and bone marrow transplant expertise is changing cancer care at Ohio State
For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis on patients’ quality of life.
Beyond TKIs: Synthetic Lethal Approaches and Targeted Therapies to Watch in Lung Cancer
Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.
Genomic Features May Define Patient Selection in KRAS-mutated NSCLC
Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.
Survivorship and Visual Storytelling with Anna Rathkopf
In this episode, host Shikha Jain, MD, speaks with Anna Rathkopf about the mental and physical toll of cancer treatment and survivorship, using photography to…
Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ
This phase 1 nonrandomized clinical trial evaluated the safety and efficacy signaling of combined pembrolizumab and mRNA-2752 to treat patients with high-risk ductal carcinoma in…
Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.
Second Cycle of Medicare Drug Price Negotiations Includes 4 Oncologic Agents
The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib,…
ECHR condemns Italy’s response to toxic waste crisis
In a landmark judgement, the European Court of Human Rights (ECHR) has ruled that Italy is not protecting the right to life of 2·9 million…
